BSEBoard Meeting13h ago · 9 Nov 2026, 05:17 pm
1.Unaudited Standalone Financial Results for the quarter ended 30th September 2026 alongwith Auditors' Limited Review Report thereon; 2. Appointment of M/s V. J. Talati & Co. as the Cost Auditors of the Company for the financial year ending 31st March, 2027; and 3. Postal Ballot Notice
Medico Remedies Ltd · 540937
✦ AI SummaryResults
Medico Remedies Ltd announced unaudited standalone financial results for the quarter ended 30th September 2026, along with auditors' limited review report. The company also appointed M/s V. J. Talati & Co. as the Cost Auditors for the financial year ending 31st March 2027, and issued a postal ballot notice.
Analysis Scores
Earnings Impact6/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Medico Remedies Ltd - 540937 - Board Meeting Outcome for Intimation Under Regulation 30 (Read With Part A Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations')
Attachments (1)
📄pdf
Download →
6e9487e0-e7de-4125-bc6a-3ed39de7999f.pdf
View document text
Date: 9th November, 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza,
Dalal Street Bandra Kurla Complex, Bandra (East)
Mumbai – 400001 Mumbai-400051
Scrip Code: 540937 Symbol: MEDICO
Dear Sir/Madam,
Re.: Outcome of Board Meeting held today
Sub: Intimation under Regulation 30 (read with Part A of Schedule III) (Listing Obligations and
Disclosure Requirements) Regulations, 2015 ("Listing Regulations”)
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 9th
November, 2026 has, inter alia considered and approved the following:
1. Unaudited Standalone Financial Results for the quarter ended 30th September 2026 alongwith Auditors’
Limited Review Report thereon;
2. Appointment of M/s V. J. Talati & Co. as the Cost Auditors of the Company for the financial year ending
31st March, 2027; and
3. Postal Ballot Notice
The requisite disclosure, pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange
Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular
No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure 'A'.
We wish to inform you that the Board Meeting commenced today at 4:30 P.M. and concluded at 5:15 P.M.
Kindly take the same on record.
Thanking you,
FOR MEDICO REMEDIES LIMITED
HARESH MEHTA
CHAIRMAN & WHOLE-TIME DIRECTOR
DIN: 01080289
Encl: As above
Annexure-A
Disclosure pursuant to Para A of Part A of Schedule Ill of Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155
dated 11th November, 2024
Appointment of Cost Auditor
Sr. Particulars Disclosure
1 Reason of change viz Appointment of Cost Auditor for FY 2026-27
appointment, resignation,
removal, death or otherwise
2 Date of Appointment & Term of Appointment approved in the Board meeting held on 9th November
appointment 2026 as Cost Auditor for FY 2026-27 to issue Cost Audit Report as per
the provisions of the Companies Act, 2013
3 Brief Profile M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No.
R00213) has experience and expertise in Cost Audit over the years.
The firm also provides Guidance for Maintenance of Cost Accounting
Records as prescribed under the Companies (Cost Records and Audit)
Rules, 2014 and certification as regards maintenance of Cost Records
by the Company.
Shah Shroff •
& Associates
Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone
Financial Results of Medico Remedies Limited pursuant to regulation 33 ofSEBI (Listing
Obligations and Disclosure Requirements), Regulation 2015, as amended
THE BOARD OF DIRECTORS
MEDICO REMEDIES LIMITED
1105/1106, 11th Floor, Hubtown Solaris
Opp. Telli Galli, N S Phadke Marg,
Andheri East, Mumbai -400069
Dear Sirs,
Re: Limited Review Report of the Unaudited Standalone Financial Results for the
quarter and half year ended 30th September, 2026
We have reviewed the accompanying Statement of unaudited Standalone Financial Results of
Medico Remedies Limited ("the Company") comprising of profit and loss account, statement
ofa ssets and liabilities and statement of cash flow for the half year ended 30th September, 2026,
together with the notes thereon, ("the Statement") attached herewith, being submitted by the
Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and
Disclosure Requirements), Regulation 2015 ('the Regulation') as amended (the "Listing
Regulations").
This Statement which is the responsibility of the Company's Management has been reviewed
by Audit Committee and approved by the Board of Directors at their respective meetings held
on 09th November, 2026 has been prepared in accordance with the recognition and
measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial
Reporting" (IND AS 34), prescribed under section 133 of the Companies Act, 2013 read with
relevant rules issued thereunder and other accounting principles generally accepted in India.
Our responsibility is to expre~s a conclusion on the statement based on our review.
We conducted our review of the Statement in accordance with the Standard on Review
Engagement (SRE) 2410, "Review of Interim Financial lnfonnation perfonned by the
Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India.
This Standard requires that w~ plan and perform the review to obtain moderate assurance as to
whether the Statement is free of material misstatement. A review is limited primarily to
inquiries of the company personnel and analytical procedure applied to financial data and thus
provide less assurance than an audit. We have not performed an audit and, accordingly, we do
not express an audit opinion.
A703, W111Sway Complex, Old Police Linc, Andhcri (E), Mumbai -400 069.
Tel: +91-22-6127 7488 / 6697 3268 Email: shahshroff@gnwl.com
Shah Shroff •
Continuation Sheet
& Associates
Based on our review conducted as above, nothing has come to our attention that causes us to
believe that the accompanying statement of Unaudited Standalone Financial Results prepared
in accordance with applicable Indian Accounting Standard specified under section 133 of the
Companies Act, 2013 as amended, read with relevant rules issued thereunder and other
recognized accounting principles and policies has not disclosed the information required to be
disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that
it contains any material misstatement.
For Shah Shroff & Associates
Chartered Accountants
Firm Registration No.: 128920W
Partner
Number -103277
UDIN: ,J,, 0~1:J-,:t116'DTG 1Cfl
Place: Mumbai
Date: 09.11.2026